NUVB — Nuvation Bio Inc.

Summary of Nuvation Bio's Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $13.1 million, with $7.7 million in net product revenue from IBTROZI.
• New Patient Starts: 204 new patients began treatment with IBTROZI in Q3, averaging over 15 new starts per week.
• Gross to Net Revenue: Approximately 20%, expected to increase slightly over time.
• Cash Position: $549 million in cash, cash equivalents, and marketable securities, with an additional $50 million available under a term loan.
• Operating Expenses: R&D expenses were $28.8 million, and SG&A expenses were $37.4 million, primarily for commercialization efforts.

2. Strategic Updates and Business Highlights

• IBTROZI Launch: The launch is progressing well, with strong physician support and a growing patient base. The company aims to establish IBTROZI as the new standard of care for ROS1-positive non-small cell lung cancer.
• Clinical Data: Updated data shows a median duration of response (DOR) of 50 months for TKI-naive patients, reinforcing IBTROZI's efficacy and safety profile.
• Expansion Plans: Initiated the TRUST-IV study for IBTROZI as adjuvant therapy in early-stage non-small cell lung cancer. Regulatory approval received in Japan, with expectations for reimbursement approval leading to a $25 million milestone payment.
• Pipeline Development: Progress on safusidenib for IDH1-mutant glioma, with plans for a pivotal Phase III study.

3. Forward Guidance and Outlook

• Patient Growth: Anticipated continued growth in patient starts, with expectations for a significant increase in first-line patient adoption as awareness and testing improve.
• Revenue Projections: While not providing specific revenue guidance, management indicated comfort with current consensus estimates for 2026 at approximately $115 million, driven by the long DOR of IBTROZI.
• Market Expansion: Plans to finalize a European commercialization partnership in Q4, which could enhance revenue streams.

4. Bad News, Challenges, or Points of Concern

• Competitive Landscape: Concerns about upcoming competitors entering the market, although management expressed confidence in IBTROZI's unique efficacy metrics compared to existing therapies.
• Market Access: Although payer engagement is strong, the company must continue to navigate the complexities of reimbursement and coverage, particularly in new markets.
• Long Study Timelines: The Phase III study for safusidenib is expected to take several years to complete, with data not anticipated until 2029, which may limit short-term visibility.

5. Notable Q&A Insights

• Sales Guidance: Management refrained from providing specific sales guidance but noted strong performance in Q3 as a positive indicator for future growth.
• Patient Demographics: Acknowledged that the majority of new patients are currently coming from academic centers, with expectations for more community-based patient starts as awareness grows.
• Market Share: While difficult to quantify due to data limitations, management believes they are capturing a significant share of the market, outperforming competitors in early launch metrics.
• Expanded Access Program: Very few patients transitioned from the expanded access program to commercial treatment, indicating that most patients are new diagnoses.

Overall, Nuvation Bio's Q3 2025 results reflect a strong start for IBTROZI's commercial launch, with promising clinical data and strategic initiatives aimed at expanding market presence, despite facing competitive pressures and the challenges of navigating the healthcare landscape.